{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:44:08Z","timestamp":1793058248566,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>\n                    We developed and validated an architecture-based grading for clear cell renal cell carcinoma (ccRCC) in an observational retrospective cohort study including 506 tumors (principal cohort, n=254; validation cohort, n=252). Study endpoints were disease-free survival (DFS) and cancer-specific survival (CSS). Relationships with outcome were analyzed using Harrell concordance index, time-dependent receiver operating characteristic curve, area under curve, and Cox regression model. An architecture-based grading was devised on positive likelihood ratio (LR+) for DFS at 50 months as follows: grade 1 (LR+&lt;0.8), cystic, compact, acinar, clear cell papillary RCC-like, and\/or regressive patterns; grade 2 (1.2\u2264LR+&lt;5), large nest, alveolar, papillary, chromophobe\/oncocytic cell-like, eosinophilic hyaline globule, and\/or intratumoral inflammatory reaction patterns; grade 3 (5\u2264LR+&lt;10), rhabdoid, tumor giant cell, enlarged vascular space, and\/or hereditary leiomyomatosis renal cell carcinoma (HLRCC)-like patterns; grade 4 (LR+\u226510), sarcomatoid, infiltrative growth patterns, and lymphatic invasion. In the principal cohort, 3-tier (grades 1-2, 3, and 4) and 4-tier architectural scores outperformed World Health Organization\/International Society of Urological Pathology, and World Health Organization\/ International Society of Urological Pathology+necrosis gradings for DFS and CSS, and constituted an independent predictor for DFS (hazard ratio [HR]=5.91;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;6.7E-10) and CSS (HR=4.49;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =2.2E-03), retained in the localized (pT1-3N0M0) ccRCC subgroup (HR=6.10;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =1.3E-07 for DFS, and HR=20.09;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =9.4E-05 for CSS). On comparing with integrated staging systems, architectural grade with 1 morphologic datum remained an independent predictor of CSS, as did University of California Los Angeles Integrated Staging System and SSIGN, and was associated with the highest HR (HR=2.60;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =9.1E-04 in all patients; HR=4.38;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =2.0E-05 in the localized ccRCC subgroup). Architecture-based score for ccRCC outperforms all other morphologic grading systems and constitutes an independent predictor for DFS and CSS. As the predictive values of 3-tier and 4-tier architecture-based scores were similar throughout the study, we proposed to keep the simplified version as the final score, and to define 3 risk groups as follows: low risk (grades 1 to 2), intermediate risk (grade 3), and high risk (grade 4).\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000001025","type":"journal-article","created":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T21:58:57Z","timestamp":1516485537000},"page":"423-441","source":"Crossref","is-referenced-by-count":51,"title":["Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment"],"prefix":"10.1097","volume":"42","author":[{"given":"J\u00e9r\u00f4me","family":"Verine","sequence":"first","affiliation":[{"name":"Department of Pathology, Saint-Louis Hospital, AP-HP"},{"name":"CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI)"},{"name":"University Paris Diderot, Sorbone Paris Cit\u00e9, UMR E_5, Saint-Louis Hospital"},{"name":"University Paris Diderot, INSERM, UMR_S1165"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Colin","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Nheb","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saint-Louis Hospital, AP-HP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Prapotnich","sequence":"additional","affiliation":[{"name":"Department of Urology, Institut Mutualiste Montsouris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[{"name":"Department of Urology, Saint-Louis Hospital, AP-HP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Cathelineau","sequence":"additional","affiliation":[{"name":"Department of Urology, Institut Mutualiste Montsouris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Desgrandchamps","sequence":"additional","affiliation":[{"name":"CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Research Division in Hematology and Immunology (SRHI)"},{"name":"University Paris Diderot, Sorbone Paris Cit\u00e9, UMR E_5, Saint-Louis Hospital"},{"name":"Department of Urology, Saint-Louis Hospital, AP-HP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Mongiat-Artus","sequence":"additional","affiliation":[{"name":"University Paris Diderot, INSERM, UMR_S1165"},{"name":"Department of Urology, Saint-Louis Hospital, AP-HP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Feugeas","sequence":"additional","affiliation":[{"name":"University Paris Diderot, INSERM, IAME, UMR_1137, Paris"},{"name":"University of Franche Comt\u00e9, INSERM, U1098, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.eururo.2014.06.053","article-title":"Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers","volume":"66","author":"Gulati","year":"2014","journal-title":"Eur Urol"},{"issue":"suppl 2","key":"R2-20230922","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/modpathol.2008.183","article-title":"Advances and controversies in grading and staging of renal cell carcinoma","volume":"22","author":"Delahunt","year":"2009","journal-title":"Mod Pathol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","article-title":"Prognostic significance of morphologic parameters in renal cell carcinoma","volume":"6","author":"Fuhrman","year":"1982","journal-title":"Am J Surg Pathol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.humpath.2013.10.033","article-title":"Clear cell renal cell carcinoma with a syncytial-type multinucleated giant tumor cell component: implications for differential diagnosis","volume":"45","author":"Williamson","year":"2014","journal-title":"Hum Pathol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/his.12239","article-title":"Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma","volume":"63","author":"Williamson","year":"2013","journal-title":"Histopathology"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.eururo.2014.04.022","article-title":"Clear cell renal cell carcinoma (ccRCC) with hemangioblastoma-like features: a previously unreported pattern of ccRCC with possible clinical significance","volume":"66","author":"Montironi","year":"2014","journal-title":"Eur Urol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/PAS.0000000000000514","article-title":"Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: combined morphologic, immunohistochemical, and cytogenetic analysis","volume":"39","author":"Williamson","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/01.ju.0000135837.64840.55","article-title":"Multi-institutional validation of a symptom based classification for renal cell carcinoma","volume":"172","author":"Patard","year":"2004","journal-title":"J Urol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAS.0b013e318270f71c","article-title":"A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2016.05.034","article-title":"Application of the Stage, Size, Grade, and Necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients","volume":"71","author":"Parker","year":"2017","journal-title":"Eur Urol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2001.19.17.3792","article-title":"Validation of the ucla integrated staging system for patients with renal cell carcinoma","volume":"19","author":"Zisman","year":"2001","journal-title":"J Clin Oncol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000353863","article-title":"Diagnostic accuracy measures","volume":"36","author":"Eusebi","year":"2013","journal-title":"Cerebrovasc Dis"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1525-1497.2002.10750.x","article-title":"Simplifying likelihood ratios","volume":"17","author":"McGee","year":"2002","journal-title":"J Gen Intern Med"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/hupa.2002.30210","article-title":"Renal epithelial neoplasms: the diagnostic implications of electron microscopic study in 55 cases","volume":"33","author":"Krishnan","year":"2002","journal-title":"Hum Pathol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00428-013-1379-3","article-title":"Differential diagnosis of primary benign vascular tumors and\/or tumor-like lesions of the kidney: immunohistochemical stains should not be restricted to vascular and pan cytokeratin markers","volume":"462","author":"Verine","year":"2013","journal-title":"Virchows Arch"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/PAS.0b013e31820f6d11","article-title":"Sporadic hemangioblastoma of the kidney: an underrecognized pseudomalignant tumor?","volume":"35","author":"Verine","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00428-009-0741-y","article-title":"Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity","volume":"454","author":"Verine","year":"2009","journal-title":"Virchows Arch"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/PAS.0000000000000583","article-title":"Renal neoplasms with overlapping features of clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma: a clinicopathologic study of 37 cases from a single institution","volume":"40","author":"Dhakal","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry","volume":"38","author":"Chen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2010.08.031","article-title":"Hereditary renal cancer syndromes: an update of a systematic review","volume":"58","author":"Verine","year":"2010","journal-title":"Eur Urol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1309\/AJCPIMPE6ZFT8AME","article-title":"Growth pattern, an important pathologic prognostic parameter for clear cell renal cell carcinoma","volume":"140","author":"Fukatsu","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.juro.2011.07.034","article-title":"External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology","volume":"186","author":"Pichler","year":"2011","journal-title":"J Urol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s11255-016-1314-z","article-title":"Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma","volume":"48","author":"Kara","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2015.01.002","article-title":"Impact of rhabdoid differentiation on prognosis for patients with grade 4 renal cell carcinoma","volume":"68","author":"Zhang","year":"2015","journal-title":"Eur Urol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/PAS.0000000000000690","article-title":"Tumor necrosis adds prognostically significant information to grade in clear cell renal cell carcinoma: a study of 842 consecutive cases from a single institution","volume":"40","author":"Khor","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.semdp.2015.02.008","article-title":"Outcome prediction for patients with renal cell carcinoma","volume":"32","author":"Lohse","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2014.05.027","article-title":"International Society of Urological Pathology grading and other prognostic factors for renal neoplasia","volume":"66","author":"Delahunt","year":"2014","journal-title":"Eur Urol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0b013e3181e4ee32","article-title":"A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors","volume":"34","author":"Sica","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/PAS.0b013e31829a85d0","article-title":"Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations","volume":"37","author":"Trpkov","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.eururo.2013.12.001","article-title":"Re: Jimsgene Sanjmyatav, Sven Hauke, Mieczyslaw Gajda, et al. Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Eur Urol 2013;64:689\u2013691","volume":"65","author":"Verine","year":"2014","journal-title":"Eur Urol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201804000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T18:38:56Z","timestamp":1695407936000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201804000-00001"}},"subtitle":["Comparisons With WHO\/ISUP Grade and Integrated Staging Systems"],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001025","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}